Lenalidomide

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Myelodysplastic syndrome, Abstract, Rituximab, AACR, University, Cell death, ASH, Cancer prevention, Sarcoma, Multiple myeloma, Drug discovery, Clinical trial, Bone marrow, Lenalidomide, NHL, Chronic myelomonocytic leukemia, American Association for Cancer Research, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Research, MD Anderson Cancer Center, Monroe Dunaway Anderson, Salinicola salarius, Azacitidine, Protein, Acquisition, Patent, Patient, Mouse, Research institute, Ewing sarcoma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Factorization of polynomials, Food, Cancer Prevention and Research Institute of Texas, Cryptocurrency, Video game, Pharmaceutical industry, Rail freight transport, Vaccine

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Retrieved on: 
Thursday, March 23, 2023
Palonosetron, Hepatocellular carcinoma, Marketing, Fulvestrant, G&A, Acquisition, Investment, Patient, Ministry of Health (Turkey), Oncology, Toronto Stock Exchange, R, IAS, News, MXN, DLBCL, Lenalidomide, Infection, Acute leukemia, COP, Health maintenance organization, Net, HIV disease progression rates, Growth, Fungal infection, ANVISA, Tafasitamab, HER2, COVID-19, CAD, BRL, Ministry, CLP, GBT, S&M, Therapy, Thyroid cancer, Hallmark-Sonali Bank Loan Scam, HIV, MOH, Income tax, Woman, EBITDA, ASCT, Bank, HCV, LATAM, Financial adviser, Pharmaceutical industry, Film industry, Cryptocurrency, Security (finance), Bookkeeping, Rigel, Health, Research, Bancolombia, Knight, Novartis

Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.

Key Points: 
  • Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.
  • General and administrative: For the quarter ended on December 31, 2022, there was no significant variation in General and administrative expenses.
  • Research and development expenses: For the quarter ended on December 31, 2022, there was no significant variation in Research and development expenses.
  • In addition, during the fourth quarter of 2022, Knight also submitted a branded generic of for regulatory approval in Chile and Colombia.

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Constellation, Progression-free survival, Cancer, Research, Conference, FSE, Workforce, Lenalidomide, DLBCL, Webcast, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Conference call, Doctor of Philosophy, Cryptocurrency, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.

Key Points: 
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter  2022 and € 3.0 million for the full year of 2022.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Constellation, Progression-free survival, Cancer, FSE, Workforce, Lenalidomide, DLBCL, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Doctor of Philosophy, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Molecule, Phosphatidylinositol, AACR, Lenalidomide, Lung cancer, APC Activator, Abstract, DLBCL, Clinical trial, Refractory, Anemia, Relapse, Potent, Tumor microenvironment, Phosphatase, BTK, BET inhibitor, Drug resistance, Bone marrow, MPN, Myeloproliferative neoplasm, ALK2, American Association for Cancer Research, Efficacy, Treatment, Fibroblast growth factor receptor, FGFR, Pharmaceutical industry, Vaccine, Patient, Macrophage, Incyte, Primary myelofibrosis, Pemigatinib

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
  • ET)
    Five-Year Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase 2 L-MIND Study1(Abstract #CT022.
  • ET)
    For registered attendees, the virtual meeting platform and all on-demand sessions will be available through July 19, 2023.
  • More information regarding the AACR Annual Meeting 2023 can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/ .

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MD Anderson Cancer Center, Therapy, Doctor of Philosophy, Medicare Part D, MD, CMO, KAAG1, NYSE, Drug development, Lung cancer, University, Lenalidomide, AXL, S&M, Investment, Patient, Mitsubishi Tanabe Pharma, Medicare (United States), Sarcoma, ASH, Growth, Polatuzumab vedotin, Medicare, CD22, DLBCL, AbbVie, ADC, CFO, Sale, PIN, IHC, Antibody, Roche, G&A, Society, Infrastructure Investment and Jobs Act, Pharmaceutical industry, Video game, Fine chemical, Management, Coal, Reinsurance, EU

ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.
  • “We made good progress across the business in 2022, including laying the crucial groundwork for the ongoing ZYNLONTA launch.
  • The sequential third quarter to fourth quarter slight decline of 7.0% in net sales was due to higher gross-to-net and individual ordering account fluctuations.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2022 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Retrieved on: 
Friday, January 27, 2023
Rituximab, Food, Lymphoma, Lymphatic system, Lenalidomide, Blood, NHL, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Neoplasm, Investigational New Drug, B-cell lymphoma, Pharmaceutical industry, Vaccine, Salinicola salarius

HOUSTON, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of preclinical data showing SP-3164’s activity in non-Hodgkin’s lymphoma (NHL) animal models. In a model of diffuse large B-cell lymphoma, SP-3164 exhibited synergistic activity with the approved anti-CD20 drug rituximab, resulting in the complete elimination of tumors in 50% of treated mice. The combination also performed significantly better than the approved regimen, lenalidomide and rituximab. These data were presented by Aundrietta Duncan, Ph.D., Salarius’ director of non-clinical development, at the inaugural Molecular Glue Drug Development Summit.

Key Points: 
  • In a model of diffuse large B-cell lymphoma, SP-3164 exhibited synergistic activity with the approved anti-CD20 drug rituximab, resulting in the complete elimination of tumors in 50% of treated mice.
  • The combination also performed significantly better than the approved regimen, lenalidomide and rituximab.
  • These data were presented by Aundrietta Duncan, Ph.D., Salarius’ director of non-clinical development, at the inaugural Molecular Glue Drug Development Summit.
  • Dr. Duncan’s presentation is available for viewing in the Investors Events and Presentations section of Salarius’ website here .

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Retrieved on: 
Wednesday, December 28, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, HKEX, National Health Commission, Tafasitamab, Food, European Medicines Agency, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Guangdong-Hong Kong-Macau Greater Bay Area, SSE, ASCT, DLBCL, NMPA, Immunotherapy, Patient, Lenalidomide, FDA, Department of Health and Social Care, EMA, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “The Hong Kong approval of tafasitamab and lenalidomide will not only provide access to eligible DLBCL patients in the region, but may also help patient access in the Greater Bay Area soon.
  • As part of this early access program, the first prescription of tafasitamab in combination with lenalidomide was filed in July at the Ruijin Hainan Hospital for an eligible DLBCL patient.
  • Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of relapsed or refractory DLBCL patients who are not eligible for autologous stem cell transplantation (ASCT).

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, Cancer prevention, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Cancer Prevention and Research Institute of Texas, Letter, Food, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, Lenalidomide, Deuterium, SUSAR, Drug discovery, Ewing's sarcoma, Drug development, Research, Society, NHL, Research institute, Biology, Patient, MD Anderson Cancer Center, Rituximab, Vaccine, Pharmaceutical industry, Salinicola salarius, IND, DLBCL

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that yesterday Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, presented positive SP-3164 preclinical data at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • Avadomide is an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy efficacy in non-Hodgkin’s lymphomas (NHL) and other hematologic malignancies.
  • This, along with the data presented at ASH showing compelling SP-3164 activity in lymphoma models, supports SP-3164’s potential in NHL for the clinical trial planned for 2023.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.
  • Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.